Business Wire

CSG Cloud-Native Rating and Charging Solution Now in Production With Customers Worldwide

29.4.2020 15:00:00 EEST | Business Wire | Press release

Share

CSG ® (NASDAQ: CSGS) today introduced a new addition to its Ascendon platform, CSG Ascendon Rating & Charging, a fully cloud-native, serverless charging software as a service (SaaS). Now actively in use, the solution provides CSG customers with real-time online charging functionality and rating capabilities to support and scale for wireless and digital services offered today and in the future.

As device types and connections surge, operators need highly flexible solutions to rate and charge for events in real-time, at scale, and for innovative monetization models. As a fully hosted, multi-tenant, SaaS solution architected on Amazon Web Services (AWS), Ascendon Rating and Charging elastically scales when volumes fluctuate allowing for efficient and cost-effective management of network resources.

The solution can be used to configure any combination of products, offers, and eligibility rules, as well as how they are sold across channels, in a matter of minutes. It enables balance sharing across multiple devices and services and gives operators the ability to charge dynamically based on network events, with real-time notifications to help engage the customer.

The solution also provides online charging system (OCS) capabilities including real-time authorization and balance management for voice, data, content and digital services; usage processing and rating; and dynamic entitlements that ensure accurate charging.

“Modern business models are centered around emerging digital offers that can be deployed quickly and cost effectively,” said Chad Dunavant, head of global product management, CSG. “CSG Ascendon Rating and Charging is a new breed of cloud-native SaaS that helps operators successfully deploy new services like 5G, while helping them manage risk and optimize operational costs.” (video)

Key technical features include:

  • Resiliency by design: High availability and geographically distributed across multiple AWS availability zones (AZs) to help ensure a fail-proof environment. It exceeds the resilience of traditional data centers by utilizing multiple AZs by design, providing a minimum of active-active-active configuration.
  • Grow as you go: Provides an unlimited supply of cloud-compute and scalability through AWS, taking the guesswork out of required capacity and eliminating the need for large upfront capital expenditures, lowering operational costs.
  • Fully featured and highly flexible: Configurable to support any wireless or digital service or bundled offer, as well as multiple charging models including pre-pay, post-pay, currency conversion, payments, invoicing, and adjustments.
  • Fully managed: Complete management of operations and issues, as well as automated quarterly releases deployed by CSG, allowing for rapid deployment of new features and efficient management of resources internally.
  • Network/platform agnostic: Charge for any transaction across any network or service platform.

This solution is part of CSG Ascendon, a globally recognized and award-winning digital monetization platform that has helped some of the world’s most innovative companies not just compete but thrive in the digital economy. Ascendon is part of CSG’s Revenue and Customer Management suite of end-to-end capabilities that support more than 500 companies globally, providing them with flexible and configurable technology solutions that help them monetize and digitally enable their customer experiences.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Brad Jones
Public Relations
CSG
+1 (303) 200-3001
brad.jones@csgi.com

David Banks
Investor Relations
CSG
+1 (303) 200-3127
david.banks@csgi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye